Search the Newsreel

Orchestra BioMed (OBIO) Earnings Date and Reports 2026

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Inc. announced its second-quarter 2026 financial results, highlighting significant progress in its clinical programs for age-related brain disorders. The company is actively seeking a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB) after new analyses reinforced its …

CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely

CervoMed (NASDAQ:CRVO) is highlighted as a company that needs to carefully manage its cash burn, as it currently has only about 11 months of cash runway based on its June 2026 cash balance and annual burn rate of US$28 million. The article notes that …

Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen has downgraded Generate Biomedicines (NASDAQ:GENB) from "Hold" to "Sell," despite a broader analyst consensus of "Moderate Buy." This comes after the company reported a quarterly loss of $0.52 per share, missing estimates, and generated $6.31 million in revenue. Institutional activity includes …

CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash

CervoMed (NASDAQ: CRVO) reported a Q2 2026 net loss of $6.6 million and a first-half net loss of $14.5 million, primarily due to R&D and administrative expenses without product revenue. The clinical-stage biotech successfully raised approximately $20.5 million through a private placement and a …

Ping An Biomedical (NASDAQ: PASW) switches auditors from WWC to Edston

Ping An Biomedical Co., Ltd. (NASDAQ: PASW) announced a change in its independent auditors, replacing WWC, P.C. with Edston Global PAC. The board resolved not to reappoint WWC on August 5, 2026, and appointed Edston effective August 6, 2026. The company confirmed there were …

Advanced Biomed Inc (ADVB) Stock News Today

This page provides an overview of Advanced Biomed Inc (ADVB) stock, including its current price, market capitalization, P/E ratio, and links to various financial data and analysis tools. The main section indicates that more news will be coming soon for the company.

CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary

CervoMed Inc. reported a net loss of ($6.57M) and ($0.64) EPS for the 2026 quarter, with grant revenue of $0, a significant drop from the prior year's $1.76M. The company completed $20.5M in financing for R&D, focusing on advancing neflamapimod clinical programs, particularly for …

Ping An Biomedical Switches U.S. Auditor to Edston Global PAC

CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates

CervoMed Inc (CRVO) has an earnings forecast score of 8.00, placing it 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00, with a high of $31.00 and a low of $15.00. Based on ratings from 6 …

Orchestra Biomed Holdings Inc (OBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Orchestra Biomed Holdings Inc (OBIO) has an earnings forecast score of 8.00, placing it 65th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $12.00, with a range from $10.00 to $20.00, indicating a "Buy" trend based on …

UK's Oxford Biomedica tumbles after annual revenue forecast cut

Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions

Generate Biomedicines (GENB) is projected to experience a decline in earnings at 10.7% annually, despite an expected 41% annual revenue growth and a 1.6% EPS growth. The company, which is focused on AI-driven drug discovery with a $1.8 billion market cap, faces significant risks …

Oxford BioMedica shares fall after delays impact revenue expectations

WINNERS & LOSERS: Goodwin jumps; Oxford BioMedica trims revenue view

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Inc. has released its financial results for the second quarter of 2026 and provided a business update. This report details the company's financial performance and outlines recent developments and strategic initiatives.

Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary

Generate Biomedicines, Inc. reported Q2 2026 results with revenue of $6.3M, a 37.7% decline year-over-year, and a net loss of $67.3M, or diluted EPS of $(0.52). The company saw reduced collaboration revenue as partner obligations neared completion but advanced several clinical programs including GB-0895 …

Oxford BioMedica tanks 24% after earnings alert; brokers take stock

Oxford Biomedica Shares Slump on Deep FY2026 Revenue Downgrade

Oxford Biomedica Lowers 2026 Guidance Despite Strong Client Growth

Jupiter Infomedia Q1 Results 2026 - Find Jupiter Infomedia Q1 Earnings Result | Jupiter Infomedia Q1 results

Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash

Generate Biomedicines reported its second-quarter 2026 results, showing $6.3 million in collaboration revenue and a net loss of $67.3 million. The company held $457.4 million in cash, which is expected to fund operations into the first half of 2028, and highlighted advancement in multiple …

Generate Biomedicines Shares Fall Following Q2 Financial Results

Generate Biomedicines (GENB) shares dropped by 4.6% after the company announced its Q2 financial results, indicating a wider loss than expected. The full details of the financial performance are behind a premium paywall.

Ondine Biomedical (LSE:OBI) Makes Data Quality the Next Penny-Stock Catalyst

Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M

Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO

Generate Biomedicines (Nasdaq:GENB) - Stock Analysis

Generate Biomedicines (GENB) is utilizing machine learning for drug discovery and development, holding a market cap of US$1.8 billion. While revenue is projected to grow significantly, the company is currently unprofitable and faces risks such as declining earnings forecasts and a cash runway of …

Lifecore Biomedical Releases Q2 2026 Financial Results

Lifecore Biomedical, Inc. (LFCR) reported its Q2 2026 financial results, narrowing its loss per share to -$0.19 and exceeding revenue expectations with $34.2 million. Despite beating estimates, the company experienced a 6.2% revenue decline year-over-year due to softness in its CDMO segment. Management provided …

Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Lifecore Biomedical (NASDAQ:LFCR) reported its quarterly earnings, exceeding analyst estimates with an EPS loss of $0.19, $0.03 better than expected, and revenue of $34.17 million, surpassing the $32.02 million forecast. Despite a year-to-date revenue decline and widened net loss, the company reaffirmed its 2026 …

LFCR Stock Price and Chart — NASDAQ:LFCR

Lifecore Biomedical, Inc. (LFCR) is a pharmaceutical company specializing in hyaluronan-based products. Its stock price is currently $5.01, with a market capitalization of $189.64 million. The company's recent earnings report showed declining revenue and profit year-over-year, but management reaffirmed 2026 guidance due to cost …

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Generate Biomedicines (NASDAQ: GENB) is one of the top five largest holdings of Nvidia (NASDAQ: NVDA), run by CEO Jensen Huang. Let that sink in for a moment. The largest publicly traded company by market capitalization has roughly $10.4 million invested in a clinical-stage …

Lifecore Biomedical Inc expected to post a loss of 22 cents a share - Earnings Preview

Lifecore Biomedical Inc is anticipated to report a loss of 22 cents per share, according to an earnings preview. This forecast is based on information shared through TradingView News, indicating an upcoming financial announcement for the company.

Lifecore Biomedical, Inc. reports results for the quarter ended June 30 - Earnings Summary

Lifecore Biomedical, Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, provides an earnings summary for the company. Readers are encouraged to access the full report for detailed information.

Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million

Lifecore Biomedical reported a wider GAAP net loss of $6.2 million in Q2 FY26, with revenue decreasing by 6.2% to $34.2 million. GAAP gross profit also fell, and non-GAAP adjusted EBITDA saw a slight decrease. Despite these financial challenges, the company signed six new …

CervoMed to Share Drug Program Progress at Aug. 11 Chat

CervoMed (NASDAQ: CRVO) will participate in a fireside chat and investor meetings at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, to discuss recent progress in its neflamapimod clinical development program. The fireside chat is scheduled for 11:30–11:55 AM ET and …

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Inc. announced its participation in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. Management will discuss recent progress in the clinical development program for neflamapimod, a lead drug candidate for age-related brain …